|
**Overview**: Cannabinoids Confirmation Panel**Introduction**: The Cannabinoids Confirmation Panel is a diagnostic tool designed to confirm marijuana use using urine samples. In India, cannabis use (bhang, ganja) is prevalent in certain cultural/regional contexts (prevalence 2-5 percent in adults, higher in young males), with Delta-9-THC and THC-COOH as markers for recent/chronic use. High burden in medico-legal cases, workplace screening, drug abuse treatment, underdetection in rural areas due to limited toxicology labs. High morbidity from undetected chronic use leading to psychiatric issues or addiction. Per biochemistry practices aligned with ICMR and Narcotics Control Bureau guidelines, the test employs GC-MS/MS for confirmation over 1-2 days with high specificity, valuable for distinguishing passive exposure from active use. This diagnostic falls under drug screening and targets individuals in medico-legal, employment, or de-addiction settings, addressing accurate confirmation to guide counseling or legal action. With elevated risks due to underdetection, the test supports public health efforts by enabling precise identification and reducing substance abuse burden. Its urine-based approach ensures reliable detection.**Other Names**: Cannabinoids Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/toxicology, compliant with 2025 standards.**Historical Milestone**: GC-MS/MS gold standard; in India, used in forensic and de-addiction labs.**Purpose**: The test confirms 2 parameters including Delta-9-THC to guide marijuana use assessment, detect active/chronic exposure, inform intervention.**Test Parameters**: 1. Delta-9-THC, 2. THC-COOH.**Pretest Condition**: No fasting required; patients should report cannabis use history or screening requirement.**Specimen**: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cannabis use, frequency, last intake, or legal/employment context.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected use including legal/psychiatric issues, benefits of confirmation, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using GC-MS/MS by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, dilution, or adulteration can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive THC-COOH indicates marijuana use, necessitating specialist input. Negative may require follow-up if suspicion high.**Specialist Consultation**: Toxicologists or de-addiction specialists should be consulted for management.**Additional Supporting Tests**: Urine drug screen for confirmation.**Test Limitations**: Detects use, not impairment; comprehensive approach required.**References**: Indian Journal of Medical Toxicology 2024, Drug Screening Studies India 2023. |
